Bio-Rad Laboratories/$BIO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Bio-Rad Laboratories

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Ticker

$BIO

Primary listing

NYSE

Industry

Life Sciences Tools & Services

Employees

7,700

ISIN

US0905722072

BIO Metrics

BasicAdvanced
$6.8B
-
-$77.10
1.12
-

What the Analysts think about BIO

Analyst ratings (Buy, Hold, Sell) for Bio-Rad Laboratories stock.

Bulls say / Bears say

Bio-Rad Laboratories' Clinical Diagnostics segment demonstrated resilience, with net sales increasing by 5.3% in Q4 2023 compared to the same period in 2022, driven by strong demand for diabetes and quality control products. (biospace.com)
The company has been actively expanding its product portfolio, including the introduction of the ddPCR Microsatellite Instability (MSI) Kit and supporting software for oncology applications, positioning itself in the growing field of cancer diagnostics. (stocktitan.net)
Bio-Rad's strategic acquisition of digital PCR developer Stilla Technologies is expected to enhance its capabilities in digital PCR, supporting a diverse range of research and clinical diagnostic applications. (biospace.com)
The Life Science segment experienced a significant decline, with net sales decreasing by 19.1% in Q4 2023 compared to the same period in 2022, primarily due to lower sales of ddPCR, qPCR, and Western blotting products. (biospace.com)
Bio-Rad Laboratories cut its annual revenue growth forecast in August 2024, expecting a decline of 2.5% to 4% for the year, attributed to weak demand for clinical diagnostics products from biotech clients. (reuters.com)
The company reported a decrease in total net sales for Q1 2025, with revenue dropping to $585.4 million from $610.8 million in the same period the previous year, reflecting ongoing challenges in the academic research market, particularly in the Americas. (biospace.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.

BIO Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BIO Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BIO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs